Liver specialists

Follow us!

Eskild Endrerud

CEO
t:
(+47)93063939

Endrerud has his degree in Entrepreneurship and Business from BI Norwegian Business School, Oslo. He has experience from several start-ups, and has worked primarily with seed capital and IT. Before joining D'Liver, he was the CEO of a seed capital company in Oslo and has worked in California in this respect. He is continuously strategically involved in some of these start-ups as either a board member or the chairman.

Endrerud was hired as the CEO of D'Liver in April 2014.

Prof. Bård Smedsrød

Founder and Chief Scientific Officer
t:
(+47)99599463

Smedsrød is the founder of D’Liver and started as CSO in June 2011.

Smedsrød was a Research Fellow at the Institute of Medical Biology, University of Tromsø (Norway) in 1978-1979 and at Ann Arbor, University of Michigan (USA) in 1979-1981. From 1984-1986 he was a part time consultant at “KabiVitrum”, a medical company in Sweden and an Associate Professor at University of Uppsala Biomedical Center (Sweden) from 1985-1988. In 1988 Smedsrød moved to Tromsø and was employed as a senior scientist at the Institute of Medical Biology at University of Tromsø (Norway). He then became an Associate Professor of Cell Biology at the same institute (1990-1993) and from 1993 he was a full time professor in cell biology at the Institute of Medical Biology and head of Vascular Biology Research Group.

Dr. Kjetil H. Elvevold

Senior Scientist
t:
(+47)40220365

Elvevold was part of the team establishing D’Liver and started as senior scientist in March 2012.

Elvevold finished his M.Sc. in 1997 and was employed at the Institute of Medical Biology, University of Tromsø (Norway) until 2008. He was a Research Fellow until 2000 before starting on the Ph.D. that he finished in 2005. Thereafter he worked as a post-doc until 2008. In this period, the focus was on studies of the liver sinusoidal endothelial cells. From 2008-2012 Elvevold worked as a researcher at the Department of Clinical Pathology, University Hospital of North Norway in a commissioned research project financed by Biotec Pharmacon ASA. The role was to investigate intracellular responses upon stimulation with the immunomodulation agent beta-glucan.